CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Conditions

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced its receipt of a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” According to the update, this increases Lexaria’s portfolio to 16 awarded patents protecting its DehydraTECH(TM) drug delivery platform, with eight in the USA and eight in Australia. The new Australian patent, together with Australian Patent #2016367036 announced on August 15, 2019, are the first granted in Lexaria’s second and third patent families that differ from the company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof.” These new patents include claims for DehydraTECH technology with respect to food and beverage use and also, for the first time, for pharmaceutical applications for delivery of cannabinoids as methods of treating certain conditions. These include, but are not limited to heart disease, neurological diseases, obesity, metabolic and appetite disorders, hepatic diseases, diabetes, cancer via chemotherapy, irritable bowel syndrome (“IBS”), marijuana abuse, and opioid, alcohol, nicotine or cocaine addiction.

To view the full press releases, visit http://cnw.fm/P3Ej5

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Marijuana Legalization Takes a Step Forward in South Dakota

South Dakota is one of the few states in the U.S. that hasn’t legalized marijuana for either recreational or medicinal use. However, this may change if the recent flurry of activity to certify legalization measures eventually bears fruit on voting day in 2020. One particular ballot measure has recently earned an official explanation written by the state’s attorney general.

This measure is a rather ambitious one because it seeks to legalize medical marijuana, recreational marijuana and industrial hemp, all in one fell swoop.

The recreational use of marijuana would be legalized through an amendment to the state constitution while the state legislature would be mandated to debate and pass laws regulating medical marijuana and hemp.

In his explanation of the measure, Jason Ravnsborg, the South Dakota Attorney General, wrote that the measure seeks to legalize the use, possession, transport and distribution of cannabis by adults who are 21 years old or older. He added that cannabis plants and products produced from those plants may also be permitted under clearly defined circumstances.

Additionally, the department of revenue in the state would issue licenses to businesses that wished to cultivate, manufacture, test or distribute marijuana. Local authorities may opt out of allowing marijuana businesses to operate within their jurisdictions, according to the ballot initiative.

The AG’s explanation also emphasizes that the marijuana measure doesn’t make industrial hemp legal. Hemp can only be legalized once the legislature enacts an enabling law.

The initiative proposes that an excise tax of 15 percent should be levied on all sales of marijuana. This revenue will be used to fund the activities related to regulating the marijuana industry, and what remains will go to education and the general fund from which other state activities or programs are funded.

This explanation is similar to the one that the AG issued with respect to another proposed amendment to legalize medical cannabis in South Dakota.

The attorney general’s office also revealed that a few more measures are awaiting certification by his office. For any of those measures to make it onto the state ballot, the activists behind it must gather at least 33,921 verifiable signatures from voters in the state.

For now, it isn’t yet clear whether the campaigners will rally around one initiative rather than each group of advocates going it alone. Industry experts believe that it would be in the interest of the entire cannabis industry, including players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Marijuana Company of America Inc. (OTCQB: MCOA), to combine forces and promote one initiative so that the chances of success can be increased in this largely conservative state.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Mexican Government Seeks Public Input on Plans to Legalize Marijuana

Mexican legislators have announced plans to hold a series of public meetings in order to gather information on how the public thinks the government should handle the matter of legalizing recreational marijuana in the country. The meetings are planned for August 12, 14 and 16.

The announcements indicate that Mexicans will be free to pass on their suggestions on five different aspects of marijuana legalization. These are public health issues, matters of human rights, how to develop drugs derived from marijuana, how to prevent access to marijuana by minors and how to deal with marijuana addiction.

A translation of the information carried on the government website indicates that the move towards legalizing marijuana is motivated by several factors which include the changing attitude towards prohibition at the international level and the Supreme Court ruling that declared banning the recreational use of marijuana by adults as unconstitutional. These factors made it necessary to give serious thought to creating a regulated marijuana industry in the country.

The Mexican Senate has created a page where members of the public can find all the details about the planned meetings, as well as how interested people can register to attend the meetings in person. There is also a provision for Mexicans to submit their comments using an online form provided on the website.

The website also indicates that many bills related to marijuana legalization have been filed before the Senate and the content of those bills would form part of what is discussed during the public meetings.

Before the legislative committees start examining those bills, public input will be collected in a transparent and inclusive way so that the final legislation passed will be a true reflection of what the people of Mexico want at this time.

It should be remembered that a few months ago, Julio Ramon Salazar, the chair of the Senate Justice Committee, announced that his committee would use the summer recess to draft a law for the legalization of marijuana in the country.

While there are at least 10 bills seeking to reform Mexico’s marijuana policies, it is widely believed that the bill introduced by Olga Sanchez Cordero, the Mexican Secretary of Interior, is the one that is most likely to be passed by the lawmakers.

Marijuana reform is supported to the very top tiers of decision making in Mexico, with President Manuel Obrador saying that it is unsustainable to continue the war on drugs. He even went so far as suggesting in his National Development Plan that marijuana should be decriminalized.

Marijuana industry analysts would be eager to know what players like IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) think will be the regional ramifications of Mexico legalizing marijuana.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Congressional Bill Seeks to Protect Some Students from Losing Financial Aid Due to Marijuana Convictions

On Friday, a group of Democratic lawmakers introduced a bill in Congress that would protect some college students from losing their federal financial aid if they are convicted for possessing marijuana. The bill also states that to benefit from this protection, those affected students must complete a rehabilitation program in order to remain eligible for financial aid.

The existing law allows the government to strip students of their federal financial aid for a period that can range from a year to indefinitely based on their prior drugs convictions and the gravity of the drugs offense they have been convicted for.

The bill titled “Second Chance for Students Act” is sponsored by Reps. Gwen Moore (D-WI) and Bill Forster (D-IL). Under this proposed legislation, students who are convicted for the first time for possessing marijuana without any intention to distribute the drug can continue to receive financial assistance as long as they enroll for, and complete an approved drugs rehab program in six months.

In a press release, Rep. Forster stated that a single mistake shouldn’t cost a student their education. He added that for many students, their college education is entirely dependent on the federal financial aid that they receive. Discontinuing that aid therefore means that the student’s education, and their future, has taken a huge blow from which they could never recover.

Moore also stated that the existing law harms students of color more than any other demographic group of students since these people are particularly targeted for low-level crimes like cannabis possession.

While the bill has received a lot of support, some critics have argued that it will perpetuate a wrong mentality that people who use marijuana have a disorder for which they need rehabilitation.

Those opposed to the proposed law believe that if it is passed, it will strengthen the stigma against marijuana use and yet advocates are working hard to have the substance legalized. By treating users as people suffering from substance abuse disorder, one unwittingly admits that nobody should be using marijuana.

These critics are more comfortable with a similar draft law which was filed in the Senate by Sen. Cory Booker (D-NJ) in May. In that legislation, the question on whether a student applying for federal financial aid has ever been convicted for possessing or selling illegal drugs would be removed from the application form. Consequently, more students would be able to benefit from the protection without being coerced into signing up for drug rehab programs whose effectiveness is questionable.

It would be interesting to hear what advice cannabis industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Hemptown USA would have on this matter so that students are protected from lifelong punishment for one mistake they make.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Study Finds Legalized Recreational Cannabis a Danger to Alcohol, Not Tobacco

The recent wave of adult-use marijuana legalization across the U.S. has the potential of generating $22 billion in annual sales, but not everyone is thrilled about this development. New research that will soon be published in the Marketing Science journal shows that the alcohol industry is likely to take a hit once marijuana is legalized.

The research was done by Pengyuan, an assistant professor at the Terry College of Business (University of Georgia). He worked with Guiyang Xiong from Syracuse University.

The duo analyzed online search data taken from one of the leading web portals based in the U.S. In total, they crunched the numbers on 120 million ad impressions and 28 million anonymous searches done using this portal. The data in question covered the period January 2014 to April 2017.

The research revealed that the number of online searches done for alcohol reduced by almost 11 percent while the searches for tobacco and its products saw an increase of 8 percent.

The tobacco and alcohol industries are worth a total of $300 billion in the U.S. alone. While these two industries have been vehemently opposed to the legalization of cannabis, this research shows that the tobacco industry would be well advised to revisit their opposition to legal marijuana since opposing the advance of cannabis isn’t in their best interest.

However, the alcohol industry is justified (from an existential point of view) to oppose the onward march of legal marijuana across the country since a law legalizing marijuana at the federal level would see a major decline in the sales of alcohol. The industry therefore has to think fast and come up with ways to retain their customers if they want to retain as much of their market share as possible.

Interestingly, while this research revealed that the legalization of adult-use marijuana in a state causes 17 percent more adults to conduct online searches on marijuana, the number of people who are less than 19 show a reduced interest in marijuana (or at least they perform fewer online searches on the substance).

This again serves to dispel another perception that the legalization of recreational cannabis causes a spike in the interest shown in the substance by minors. Policymakers may therefore need to revisit their positions if they based any decisions they made upon a presumption that there will be an uptick in the number of people who show interest in the drug yet they aren’t of age.

These findings seem to make sense because pollsters have pointed out severally that many adults would opt for recreational marijuana rather than alcohol since pot doesn’t come with hangovers, weight gain and the other effects of consuming alcohol on a regular basis.

It would be interesting to know what industry players like Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) are planning to do in response to the likely spike in the opposition of the alcohol industry once the findings of this research are released and the fears of the alcohol industry are confirmed.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Study Finds Most People Buy Marijuana to Get Some Sleep

Contrary to the common perception that most people buy marijuana in order to get stoned, a new study done by the University of Miami and the Albert Einstein College of Medicine has found that the majority of those who buy marijuana in Colorado use the substance as a sleep aid. These findings are significant because recreational marijuana has been legal in the state for about 5 years now.

In the survey, 1,000 customers of two recreational marijuana stores in Colorado were asked a variety of questions about their motivation for using cannabis. 74 percent of the respondents revealed that they buy marijuana as a sleep aid while 65 percent confessed that they buy marijuana to combat pain.

About 80 percent of the survey participants who said they use marijuana for pain relief admitted that the substance was very helpful in that regard, and 88 percent of these people who had ever used opioids reported that because of using cannabis, their use of prescription opioids had reduced.

It isn’t altogether surprising that people are using cannabis to get some sleep. For long, marijuana has been known to have soporific (inducing sleep) effects and some research even suggests that CBD (cannabidiol) is responsible for expediting sleep and enhancing the overall quality of sleep that one has.

Additionally, while limited research is still available on the pain-relief effects of cannabis, some small studies indicate that marijuana may be a viable alternative to the traditional pain medication available on the market. Researchers think this is a strong possibility since the nerves which detect pain also have a large number of cannabinoid receptors.

The researchers who surveyed the cannabis buyers in Colorado wrote that if cannabis is legalized federally, there is a possibility that people’s dependence on strong prescription pain medications which have serious side effects could be reduced.

It has also been suggested that marijuana could be a good alternative if it is used as a harm reduction agent for people who are addicted to opioids.

The findings of this Colorado study are in line with another 2014 study whose findings appeared in JAMA showing that there was a reduction in the level of opioid use after marijuana was legalized.

While more research still needs to be done, industry experts think that the findings of the latest research in Colorado aren’t anything new to companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Hemptown USA since the cannabis industry has been talking about the different benefits of cannabis to different groups of people.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – It’s Official, Illinois is 11th to Legalize Recreational Marijuana

As had been widely expected, Gov. J.B Pritzker yesterday (June 25) signed a bill legalizing recreational marijuana in Illinois. This makes the state the 11th to legalize marijuana fully, joining the likes of Colorado and California.

When this new law takes effect on Jan 1, 2020, adults 21 and older will be allowed to possess up to 30grams of marijuana and non-residents will be permitted to possess a maximum of 15grams.

The signing ceremony marked the fulfillment of a pledge Gov. Pritzker made when he was campaigning for office. He promised to see the swift legalization of recreational marijuana in order to bring needed revenue to the state, correct historical wrongs occasioned during the futile war on drugs and also shift scarce law enforcement resources to more serious crimes.

This law makes Illinois the first state to legalize recreational marijuana legislatively while creating a comprehensive framework for sales across the state. The other state (Vermont) which took this path just stopped at passing a law that created an agency to work out the details of full implementation.

Until legal sales start at the beginning of 2020, it will still be illegal to possess marijuana unless one is registered on the state’s medical marijuana program.

On the market side, the legalization law creates a first-of-its-kind mechanism through which people from impoverished communities will be helped to participate in the legal cannabis industry. This help will come in the form of fee waivers, low-interest loans and other forms of preferential treatment for “equity” applicants. A portion of all revenue generated from the marijuana industry will also be reinvested in impoverished communities in order to revive their economies.

Police departments have been jittery ever since the law was drafted, and their stiff opposition led to the dropping of a provision which would have seen residents allowed to grow up to five plants for recreational use. This opportunity now went to medical marijuana cardholders who weren’t initially allowed to grow marijuana for their own use.

Police departments are now worried that it will be hard for them to stay on top of people driving under the influence of marijuana since there isn’t reliable technology to test for impairment.

Meanwhile, hopes were high among advocates that New York and New Jersey would also legalize marijuana legislatively this year but the plans in those states fizzled out during spring. There is almost no doubt among cannabis industry analysts that the whole industry, including Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), has heaved a collective sigh of relief that the momentum of state-level legalization hasn’t stalled completely.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Group Claims Federal Government Broke the Law in Cannabis Scheduling Evaluation

The Competitive Enterprises Institute, a libertarian think tank, has claimed in a formal filing that the federal government erred in the way it handled the scientific evaluation of cannabis’ therapeutic value, and the government must therefore take steps to fix the errors it made.

Their request for correction was sent to the Department of Health and Human Services (U.S. HHS). HHS had written to the DEA in 2015 and the DEA relied on that letter from HHS in determining that marijuana be classified as a Schedule 1 drug in the U.S.

According to CEI (Competitive Enterprises Institute), the letter sent by HHS lacked a very important element which is required by federal law. The federal Information Quality Act demands that such “highly influential scientific assessment” as the contents of the HHS letter to the DEA be subjected to a peer review evaluation before the information therein can be relied upon when making regulatory decisions.

No such peer review was conducted, and the CEI is demanding that HHS withdraws its letter to the Drug Enforcement Administration until the requisite peer review exercise has been done as stipulated in the law.

The DEA leaned heavily on the contents of the letter written by HHS to the effect that “marijuana has no recognized medical use in the U.S., has a high potential for abuse and doesn’t have an acceptable level of safety even when used under medical supervision.” Based on this information, the DEA rejected an application which had been made to have marijuana rescheduled in 2016.

In its letter to HHS, CEI points out that various medical associations and a huge fraction of the public in the U.S. have formed a largely different conclusion about marijuana. By law, HHS now has a maximum of 120 days within which to respond to the concerns raised by the Competitive Enterprises Institute.

Devin Watkins, an attorney for CEI, says that the federal government’s policy is likely to change if a reassessment of the matter is conducted. This is especially likely given that 33 states across the country have legalized marijuana for medical use.

The attorney added that the reassessment would be significant in ensuring that government agencies don’t brand uninformed opinions as scientific positions upon which public policies are made. Independent experts can shine a torch on the opinion of an agency and correct it if a mistake has been made.

Industry observers suspect that the entire cannabis industry, including players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Hemptown USA, are likely to follow keenly how HHS responds to the letter written by CEI.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments

CannabisNewsWire Editorial Coverage: Experiments with next-generation delivery systems appear certain to lead to better cannabis-based products.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has recently seen spectacular improvements in the effectiveness of cannabinoids thanks to its proprietary chemical delivery treatment. GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF), which has won widespread praise for its innovative medical work, has seen good trial results for a new treatment for seizures. Tilray Inc. (NASDAQ: TLRY) is supporting studies into the uses of cannabinoids to treat behavioral problems and HIV. MariMed Inc. (OTCQB: MRMD) has set up a subsidiary focused on CBD, currently the highest-profile cannabinoid product. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) has established a new research lab to develop devices for CBD consumption.

Currently, cannabis medicines are poorly absorbed by the body.
Delivery challenges increase costs and reduce effectiveness.
Select companies are working on better delivery systems.
Others are working on new medicines so that cannabinoids can improve more lives.

To view an infographic of this editorial, click here.

The Cannabinoid Waste Conundrum

The popularity of cannabinoid products — those containing active ingredients from cannabis — has created a challenge for producers. While these producers are extracting larger volumes of CBD from cannabis and hemp, much of the precious ingredient goes to waste: the human body only absorbs a small fraction of these molecules because of delivery system limitations and human physiology.

This delivery challenge causes several problems. Manufacturers must comply with regulations limiting the amount of active cannabinoid ingredients, but consumers may not be able to obtain the effect or benefit they are seeking, even when needed to overcome serious medical conditions. People could end up consuming more cannabis than they would otherwise, which is both expensive and ill-advised. And in an age when the waste of human society is ravaging the environment, it means that the cannabis industry may also be doing unneeded damage to the environment.

But thanks to the fast pace of cannabis research, a solution may be on the horizon.

Improving the Delivery of Cannabinoids

Across the industry, researchers are looking for ways to more effectively deliver CBD into the human body. Thanks to their latest breakthroughs, the scientists at Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) appear to be leading the way.

A biotech company based in British Columbia, Lexaria is currently focusing on its proprietary DehydraTECH(TM) technology. This unique technology has been developed to make medicinal compounds more suitable for human consumption in a number of ways. By combining molecules such as CBD with fatty acids at a molecular level, DehydraTECH makes it easier for the CBD to cross the body’s internal barriers. Higher levels of CBD are absorbed, and they are absorbed more quickly.

Consumers need to know this: the quantity of CBD, or any other drug, in the bottle is unimportant. What matters is how much of that CBD actually reaches the bloodstream — and even more importantly — how much reaches the brain.

Most CBD sold in CBD-infused products in America today does not reach the bloodstream. CBD mixed in water and fed to animals demonstrated the incredible power of DehydraTECH. Results announced in May showed that DehydraTECH, in combination with generic nanotech techniques, delivered CBD to the brain 1,137% more efficiently than existing industry formulations. In addition, Lexaria’s patented DehydraTECH delivered CBD into the bloodstream in just two minutes and delivered as much CBD in 15 minutes as generic doses did in 60 minutes.

Not content with these sorts of results, the company has been working on improving the power of DehydraTECH through a new second-generation version called Enhanced DehydraTECH. Lexaria’s Enhanced DehydraTECH showed remarkable properties in crossing the blood-brain-barrier, delivering 1,937% more CBD into the brain than a generic industry formulation. It also delivered between 717% and 1,098% more CBD into the bloodstream than generic CBD formulations.

Lexaria’s technological advances make it possible to manufacture capsules and edible products that deliver CBD and THC more effectively than ever before.

Satisfying Customers and Regulators

This vastly superior delivery performance holds promise to radically change the CBD industry, at a time when the sector is already going through huge change and growth.

On one level, the benefits of technology such as that being developed by Lexaria are obvious. A more efficient delivery system can do one of two things: it can make the same dose of a drug or vitamin more effective, or it can allow the same consumer effect to be achieved with a smaller dose.

The latter approach may have the widest impact and certainly has potential to shift prices. Recent legal changes in Canada and the United States have led to a surge in demand for CBD, a demand that suppliers have been unable to meet. With demand for CBD outstripping supply and a production process that involves complex technical steps, the price of CBD is relatively high. But if companies can make products that are just as effective but use smaller amounts of CBD, they can reduce their production costs and provide more products with the same raw resources. This change would allow companies to meet currently unmet demand and reduce prices, thus benefitting both the customers and the industry.

There’s also a less-obvious factor, one that industry outsiders might not consider but that companies such as Lexaria are acutely aware of. With the legalization of cannabis across Canada and hemp in the United States, regulators are stepping in to control the production, sale and dosage amounts of CBD or THC products. Limits are being set on how much CBD or THC a product can contain.

Improved delivery systems such as DehydraTECH allow companies to produce more effective products within the same legal limits. Customers can experience the highest benefit from their products while everyone stays inside the law.

Beyond CBD?

But while CBD is proving a profitable testing ground for DehydraTECH, the impact of this first-of-its-kind delivery system could potentially go far beyond this, extending into the wider medical sector.

Recent research results have shown that DehydraTECH is effective in delivering both cannabinoids and nicotine into brain tissue, thus improving the speed and effectiveness of these ingredients. The delivery system also comes with a fast-on/fast-off element, in which the effect of the drug both starts and ends quickly and clearly, providing better control over the use of the products in which drugs are used. DehydraTECH is being evaluated by the largest nicotine company in America for products utilizing oral delivery, bypassing the known disease conditions associated with current pulmonary delivery.

As a result, Lexaria’s technology already has potential medical benefits because it can be used to deliver CBD- and THC-based medicines, in addition to its applications as a solution to cigarette use. But what if it could do more?

Since DehydraTECH has been shown to work with multiple molecules, people are asking if it could be used with central nervous system drugs. By delivering drugs quickly and efficiently across the blood-brain-barrier, this innovative delivery system could enhance the speed and effectiveness of a wide range of drugs and potentially usher in a new era of treatment for a wide range of debilitating diseases. Lexaria has quietly filed patent applications for innovation in treatment options related to central nervous system diseases such as Parkinson’s and Alzheimers.

Experimenting with Cannabis

Given the importance of cannabinoids in treating some of these debilitating diseases, improved delivery systems already have clear medical advantages. Among the companies applying cannabinoids to life-changing medicines is GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF). With more than 20 years of research in the cannabis sector, GW is a global leader in developing cannabinoid medicines and was named one of Time Magazine’s 50 genius companies for this work. The company recently announced successful clinical trials of EPIDIOLEX, in which this CBD drug was used to reduce the frequency of seizures associated with tubular sclerosis complex.

Tilray Inc. (NASDAQ: TLRY), a world-leading cannabis company based in Canada, has been working to address the shortage of cannabis and CBD, investing $32.6 million in an expansion of its cultivation and manufacturing facilities. But the company isn’t just working on meeting current needs. Tilray is providing support to two clinical studies that could lead cannabinoids to transform more lives for the better. Through studies like these, the use of cannabinoids is spreading beyond its traditional territory of pain and nausea management.

MariMed Inc. (OTCQB: MRMD), a multistate cannabis company, has been improving the efficiency of its operations through vertical integration and the addition of new product lines, allowing it to more effectively deliver cannabis products to a wide range of customers. At the start of this year, the company established a subsidiary focused on CBD in response to rising sales and the changed legal status of hemp manufacturing in the US.

Lexaria’s work on DehyrdaTECH isn’t the only area where the interests of cannabis and tobacco are merging. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), a global cannabinoid company, has had its fortunes and its profile improved by an investment of C$2.4 billion from tobacco giant Altria. The company’s growth has also allowed it to establish a new global research and design center, Cronos Device Labs, in Israel. There, the company will work on devices specifically designed for the consumption of CBD.

As the technology around cannabis improves, so will the efficiency and effectiveness of cannabinoid products, lowering prices and improving outcomes for patients around the world.

For more information on Lexaria Bioscience Corp., visit Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

420 with CNW – French Medical Marijuana Experiment Starting Soon After Enabling Law is Passed

On May 28 this year, the French Senate passed a bill paving the way for marijuana to start being used therapeutically in the country. The health ministry is yet to give its approval to this law, but once it does, an experiment lasting two years will be launched to analyze the effects of marijuana on pain relief.

Patient groups put the estimate of people who would be eligible to access marijuana for pain at about 300,000-1,000,000 people. A committee is evaluating the measures which have been designed to implement the medical cannabis experiment. This committee will release their findings on June 26.

The experiment is likely to get underway in a few weeks, but the biggest challenge which will be faced is how to set up a supply chain for the industry. Initially, medical cannabis will be imported from countries where it is legal and produced to internationally acceptable standards.

As medical cannabis is imported, locally licensed producers will be busy at work setting up cultivation facilities in greenhouses or highly controlled fields. The sunlight, humidity and temperature will all be closely monitored and controlled in this unconventional agricultural undertaking.

The growers selected will be required to meet the EU rules on how to grow medical cannabis whose quality is consistent.

Medical marijuana will not be a bonanza for all who wish to use it. Physicians will only prescribe it if a patient hasn’t benefited from all the available pain treatments in the country. Of special interest will be people suffering from cancer, multiple sclerosis, some forms of epilepsy and patients undergoing palliative care.

When addressing the French Senate at the beginning of the debate on the medical marijuana bill, Senator Esther Benbassa revealed that the list of conditions for which medical marijuana could be prescribed is likely to be expanded in future to include more ailments.

Some senators, especially those from the Republican Party, fear that the medical marijuana program is being used as a Trojan horse in a bid to legalize recreational marijuana. Advocates disagree and assert that medical marijuana cannot be abused for recreational purposes since the two uses require different forms of cannabis. For example, the advocates say that therapeutic-grade marijuana is low in THC, so recreational users cannot get the psychoactive effects which they require to address their needs.

Marijuana advocates welcomed the new bill and hope that the way will be opened for exploring other purposes for which marijuana can be used. These include wellness products like supplements, oils and cannabis-infused vitamins.

Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) welcome France into the fold of countries which are benefiting from the medicinal effects of marijuana.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com